LONDON

– Novel target for idiopathic pulmonary fibrosis was discovered using BenevolentAI’s AI-drug discovery platform and experimentally validated by AstraZeneca – Announcement represents the second collaboration milestone following the addition of a novel chronic kidney disease target to AstraZeneca’s portfolio in Q1 2021 BenevolentAI, a leading clinical-stage AI drug discovery company, announced that AstraZeneca has added…

The Department of Digital, Culture, Media and Sport chooses to fund CoMP-O-RAN Dense Air Limited, along with a consortium of industry and academic partners, has been successful in securing funding from the ‘Future RAN competition – Diversifying the 5G Supply Chain’ run by the Department of Digital, Culture, Media and Sport (DCMS). The project, named […]

·  New global research examines worldwide attitudes and behaviours to sustainability and how this could redefine business’ climate action and growth strategies ·  Within a year, 3 in 5 people will start to boycott brands who don’t act on climate change ·  Almost half of consumers prepared to switch brands and services for greener alternatives ·  3 in 10 […]